If you are a Healthcare Professional and you would like to log in to access this content, please click "Login".
You are now leaving the Lilly Medical Web site
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Eli Lilly and Company does not control, influence, or endorse this site, and the opinions, claims or comments expressed on this site should not be attributed to Eli Lilly and Company. Eli Lilly and Company is not responsible for the privacy policy of any third party web sites. We encourage you to read the privacy policy of every web site you visit.
Menu closed
Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information:
Forsteo Summary of Product Characteristics (SmPC)
Forsteo® (teriparatide): Use in Patients with Monoclonal Gammopathy of Undetermined Significance
Patients with MGUS are at risk for progression to multiple myeloma or related malignancies. Patients with skeletal malignancies or bone metastases should be excluded from treatment with Forsteo (contraindication).
Monoclonal
Gammopathy of Undetermined Significance
Monoclonal
gammopathy of undetermined significance (MGUS) has an approximately
1% per year risk for progression to multiple myeloma or related
malignancies.1
If a
patient has MGUS with a likelihood of progression to multiple
myeloma, the clinician may consider not prescribing teriparatide.
Risk
factors for a patient with MGUS to progress to multiple myeloma or
related malignancies include
1.
Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined
significance and smouldering multiple myeloma: emphasis on risk
factors for progression. Br J Haematol. 2007;139(5):730-743.
http://dx.doi.org/10.1111/j.1365-2141.2007.06873.x
2.
Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of monoclonal
gammopathy of undetermined significance. N Engl J Med.
2006;354(13):1362-1369. http://dx.doi.org/10.1056/NEJMoa054494
3.
Rajkumar SV, Kyle RA, Therneau TM, et al. Serum free light chain
ratio is an independent risk factor for progression in monoclonal
gammopathy of undetermined significance. Blood.
2005;106(3):812-817. http://dx.doi.org/10.1182/blood-2005-03-1038
Glossary
BMD
= bone mineral density
IgA
= immunoglobulin A
IgM
= immunoglobulin M
M =
monoclonal
MGUS
= monoclonal gammopathy of undetermined significance
Date of Last Review:March 03, 2020
Was this answer helpful to you?
Contact Lilly
Phone
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com